Literature DB >> 25231973

Raloxifene inhibits cloned Kv4.3 channels in an estrogen receptor-independent manner.

Yun Ju Chae1, Dae Hun Kim, Hong Joon Lee, Ki-Wug Sung, Oh-Joo Kwon, Sang June Hahn.   

Abstract

Raloxifene is widely used for the treatment and prevention of postmenopausal osteoporosis. We examined the effects of raloxifene on the Kv4.3 currents expressed in Chinese hamster ovary (CHO) cells using the whole-cell patch-clamp technique and on the long-term modulation of Kv4.3 messenger RNA (mRNA) by real-time PCR analysis. Raloxifene decreased the Kv4.3 currents with an IC50 of 2.0 μM and accelerated the inactivation and activation kinetics in a concentration-dependent manner. The inhibitory effects of raloxifene on Kv4.3 were time-dependent: the association and dissociation rate constants for raloxifene were 9.5 μM(-1) s(-1) and 23.0 s(-1), respectively. The inhibition by raloxifene was voltage-dependent (δ = 0.13). Raloxifene shifted the steady-state inactivation curves in a hyperpolarizing direction and accelerated the closed-state inactivation of Kv4.3. Raloxifene slowed the time course of recovery from inactivation, thus producing a use-dependent inhibition of Kv4.3. β-Estradiol and tamoxifen had little effect on Kv4.3. A preincubation of ICI 182,780, an estrogen receptor antagonist, for 1 h had no effect on the inhibitory effect of raloxifene on Kv4.3. The metabolites of raloxifene, raloxifene-4'-glucuronide and raloxifene-6'-glucuronide, had little or no effect on Kv4.3. Coexpression of KChIP2 subunits did not alter the drug potency and steady-state inactivation of Kv4.3 channels. Long-term exposure to raloxifene (24 h) significantly decreased the expression level of Kv4.3 mRNA. This effect was not abolished by the coincubation with ICI 182,780. Raloxifene inhibited Kv4.3 channels by interacting with their open state during depolarization and with the closed state at subthreshold potentials. This effect was not mediated via an estrogen receptor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25231973     DOI: 10.1007/s00424-014-1602-3

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  57 in total

1.  Regulation of Kv4.3 voltage-dependent gating kinetics by KChIP2 isoforms.

Authors:  Sangita P Patel; Rajarshi Parai; Rita Parai; Donald L Campbell
Journal:  J Physiol       Date:  2004-01-14       Impact factor: 5.182

2.  Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.

Authors:  J A Dodge; C W Lugar; S Cho; L L Short; M Sato; N N Yang; L A Spangle; M J Martin; D L Phillips; A L Glasebrook; J J Osborne; C A Frolik; H U Bryant
Journal:  J Steroid Biochem Mol Biol       Date:  1997-04       Impact factor: 4.292

3.  Acceleration of K+ channel inactivation by MEK inhibitor U0126.

Authors:  Li-Lian Yuan; Xixi Chen; Kumud Kunjilwar; Paul Pfaffinger; Daniel Johnston
Journal:  Am J Physiol Cell Physiol       Date:  2005-08-31       Impact factor: 4.249

4.  The inactivation gate of the Shaker K+ channel behaves like an open-channel blocker.

Authors:  S D Demo; G Yellen
Journal:  Neuron       Date:  1991-11       Impact factor: 17.173

5.  Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current.

Authors:  J E Dixon; W Shi; H S Wang; C McDonald; H Yu; R S Wymore; I S Cohen; D McKinnon
Journal:  Circ Res       Date:  1996-10       Impact factor: 17.367

6.  The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation.

Authors:  Hui Liu; Lei Yang; Man-Wen Jin; Hai-Ying Sun; Yu Huang; Gui-Rong Li
Journal:  Pharmacol Res       Date:  2010-07-30       Impact factor: 7.658

7.  Accessory subunits alter the temperature sensitivity of Kv4.3 channel complexes.

Authors:  S Radicke; T Riedel; D Cotella; K Turnow; U Ravens; M Schaefer; E Wettwer
Journal:  J Mol Cell Cardiol       Date:  2013-01-03       Impact factor: 5.000

8.  Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.

Authors:  Daniel C Kemp; Peter W Fan; Jeffrey C Stevens
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

Review 9.  An estrogen receptor basis for raloxifene action in bone.

Authors:  H U Bryant; A L Glasebrook; N N Yang; M Sato
Journal:  J Steroid Biochem Mol Biol       Date:  1999 Apr-Jun       Impact factor: 4.292

10.  Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation.

Authors:  J B Grammer; R F Bosch; V Kühlkamp; L Seipel
Journal:  J Cardiovasc Electrophysiol       Date:  2000-06
View more
  1 in total

Review 1.  Estrogen receptor beta as target for colorectal cancer prevention.

Authors:  Cecilia Williams; Alfredo DiLeo; Yaron Niv; Jan-Åke Gustafsson
Journal:  Cancer Lett       Date:  2015-12-18       Impact factor: 8.679

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.